白血病细胞多药耐药逆转方法的研究进展  

Research progress on multidrug resistance reversal methods in leukemia cells

作　　者：刘威 刘克辛[1] LIU Wei;LIU Kexin(College of Pharmacy,Dalian Medical University,Dalian 116044,China)

机构地区：[1]大连医科大学药学院,辽宁大连116044

出　　处：《药物评价研究》2018年第6期937-944,共8页Drug Evaluation Research

基　　金：国家自然科学基金资助项目(81473280)

摘　　要：白血病细胞耐药的产生是药物治疗中的一大阻碍,耐药细胞过表达的跨膜转运蛋白(主要为P-糖蛋白)导致胞内药物浓度降低是产生耐药的主要原因。此外,凋亡基因的异常表达、药物作用靶点的改变也产生多药耐药(MDR)。针对这些特点寻找合适的药品与化疗药合用以增加肿瘤细胞对化疗药的敏感性,或者利用高分子材料改变释药系统,以及开发新型药物是逆转白血病细胞耐药的主要手段。通过对逆转白血病MDR的方法进行探讨,旨在为白血病治疗提供新思路。The emergence of drug resistance in leukemia cells is a major obstacle for its treatment. The over-expression of transmembrane transporter proteins（mainly P-glycoprotein） in drug-resistant cells leads to a decrease in intracellular drug concentration which is the main reason for drug resistance. In addition, the abnormal expression of apoptotic genes and the change of targets also cause multidrug resistance（MDR）. Suitable drugs combination with chemotherapeutics were found to increase the sensitivity of tumor cells to chemotherapeutic drugs, or the use of macromolecule materials to change the drug delivery system and develop new drugs are the main approaches to reverse the drug resistance of leukemia cells. Through the discussion of these ways of reversing leukemia MDR, it aims to provide new ideas for the treatment of leukemia.

关 键 词：白血病 多药耐药 P-糖蛋白 跨膜转运蛋白 抗肿瘤药 

分 类 号：R962.2[医药卫生—药理学]